GOEG_Bericht_EURIPID_GuidanceDocument_V8.1_310718.pdf 1,07MB
1000 Titel
  • Euripid guidance document on external reference pricing (ERP)
1000 Verantwortlich
  • Euripid, National Institute of Health Insurance Fund Management, Gesundheit Österreich GmbH, Státni Ústav pro Kontrolu Léčiv, Europäische Kommission ; authors: Claudia Habl (GÖG), Peter Schneider (GÖG), Gergely Németh (NEAK), Robin Šebesta (SÚKL); project Assistent: Monika Schintlmeister (GÖG)
1000 Autor/in
  1. Habl, Claudia |
  2. Schneider, Peter |
  3. Németh, Gergely |
  4. Šebesta, Robin |
  5. Schintlmeister, Monika |
  6. Gesundheit Österreich GmbH |
  7. Státni Ústav pro Kontrolu Léčiv (Prag) |
  8. Europäische Kommission (Prag) |
1000 Ausgabe
  • Final Version 8.1
1000 Katalog Id
  • HT019962893
1000 Erscheinungsort Brüssel
1000 Verlag Consumer, Health and Food Executive Agency (Chafea)
1000 Erscheinungsjahr 2018
1000 Art der Datei
1000 Publikationstyp
  1. Monografie |
  2. Report |
1000 FRL-Sammlung
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background and Research Question: The comparison of the prices of pharmaceuticals is an important element of a popular policy tool in Europe, known as ‘External Reference Pricing’ (ERP). Albeit being a commonly used policy instrument, ERP is often challenged by stakeholders by claiming potential negative effects on patients’ access or that it is hampering uptake of products in a market. Between 2016 and 2018 the Euripid Collaboration developed recommendations which are meant to guide a coordinated approach of national competent authorities regarding the use of ERP to mitigate potential negative impact for patient access. *** Methods: Electronic databases were searched for publications published during the period of 2002-2016. Grey literature, government or European Commission publications on Pharmaceutical pricing published during the same period were also searched via the Internet. In addition primary data were collected through a survey with national and EU authorities, stakeholder in the field of medicines and members of the EURIPID collaboration. The final document was prepared following a two-stage (written comments and face-to-face workshops) review process Euripid members, further national competent authorities on pricing and reimbursement of medicines, the WHO-PPRI network, European Commission policy officers and stakeholders in the field, i.e. economic operators, professional associations, patient and consumer organisations and third party payers’ associations. *** Results: Based on evidence and experience, twelve principles were developed to provide guidance when applying ERP. The principles follow the structure: Framing the issue - Things to consider - Recommendations. They cover important areas as the use of ERP for decision making, the scope/selection of reference countries, the scope/selection of medicines, the comparability of pharmaceuticals and formula used during ERP procedures. (...)
1000 Sacherschließung
ddc 330 Wirtschaft
ddc 610 Medizin und Gesundheit
ddc 615 Pharmakologie und Therapeutik
1000 DOI 10.4126/FRL01-006412800 |
1000 Hinweis
  • This report was produced under the third Health Programme (2014-2020) in the frame of a specific contract with the Consumer, Health and Food Executive Agency (Chafea) acting under the mandate of the European Commission
1000 Dateien
  1. Euripid guidance document on external reference pricing (ERP)
  2. Euripid guidance document: laymen version
1000 Umfang
  • 1 Online-Ressource (IV, 33 Seiten)
1000 Formschlagwörter
1000 Objektart monograph
1000 Beschrieben durch
1000 @id frl:6412800.rdf
1000 Erstellt am 2019-02-08T09:38:56.628+0100
1000 Erstellt von 25
1000 beschreibt frl:6412800
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet Thu Aug 22 05:06:51 CEST 2019
1000 Objekt bearb. Fri Feb 08 09:41:15 CET 2019
1000 ähnlich zu
1000 Vgl. frl:6412800
1000 Oai Id
  1. |
1000 Identisch zu
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Beschrieben durch
1000 Download
1000 Bestand
1000 Lobid

View source